Thalassemia - Pipeline Review, H2 2017 - Research and Markets

DUBLIN--()--The "Thalassemia - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Thalassemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 8, 15 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.

Key Topics Covered:

  1. Introduction
  2. Thalassemia - Overview
  3. Thalassemia - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Thalassemia - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Thalassemia - Companies Involved in Therapeutics Development
  • Acceleron Pharma Inc
  • Agios Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • bluebird bio Inc
  • Cadila Healthcare Ltd
  • Calimmune Inc
  • CRISPR Therapeutics
  • Editas Medicine Inc
  • Errant Gene Therapeutics LLC
  • Gamida Cell Ltd
  • Gilead Sciences Inc
  • Incyte Corp
  • Ionis Pharmaceuticals Inc
  • IRBM Science Park SpA
  • Kiadis Pharma NV
  • La Jolla Pharmaceutical Company
  • Merck & Co Inc
  • Protagonist Therapeutics Inc
  • Sangamo Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/research/wzr54n/thalassemia

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs, Hematological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Cardiovascular Drugs, Hematological Drugs